I make a donation

REMINDER

Evaluate the effect of eplerenone on cardiovascular mortality and morbidity in patients having a myocardial infarct under treatment

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Impact of eplerenone on cardiovascular outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

date de réalisation

2010

nombre de patients

1013

nombre de centres participants

68 centers in 11 countries

type de financement

Private (Pfizer)

Référence

NCT01176968

A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction (REMINDER)

Study Description

We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

source clinicaltrials.gov

Publication

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure : the Randomized Double-Blind Reminder Study
Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent, Faiez Zannad, REMINDER Investigators
Publicated in European Heart Journal

Presentation

ESC2017 - ALBATROSS & REMINDER update
powerpoint pdf

Autres études

ABYSS

En cours

Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI

ANCHOR

En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients